Global 1300 users industry-leading Medidata Solutions, the cloud clinical Solutions, to develop innovative medical Solutions, improve the level of clinical operations, global scientific modeling, simulation and digital assets combination form of knowledge and expertise to accelerate the development of personalized medicine, benefit the life science industry, patients will also benefit from a drug development, clinical trials, manufacturing and commercial platform effect.

On June 13, 2019, Shanghai, China -- daxo systems (euronext Paris: #13065, sy.pa) and Medidata Solutions, Inc. (NASDAQ: MDSO) announced the signing of a definitive agreement to acquire Medidata in a pure cash transaction ata price of $92.25 per share and a market value of $5.8 billion. Medidata Solutions is a leading digital transformation company in the life sciences industry, dedicated to clinical development, intelligent optimization of business and real-world environmental data. The acquisition was unanimously approved by the boards of directors of both companies. Medidata had revenue of $636 million in its last fiscal year, which ended Dec. 31, 2018. With the acquisition of us-based Medidata and its clinical business solutions, dassault systems will further strengthen its position as a technology company by providing an integrated business experience platform for the life sciences industry, supporting research and development, clinical trials, manufacturing, and commercialization of new therapies and health technologies in an end-to-end manner. Bernard Charles, vice chairman and CEO of daxos, said: "today's acquisition is a major milestone for the life sciences industry and demonstrates the tremendous value of virtual worlds in developing complex personalized medicine and patient-oriented experiences. Multidisciplinary innovation and industrial development require a platform-based approach that connects people, ideas and data. Medidata is a leader in clinical trials and complements 3DEXPERIENCE's collaborative life science solutions.

Medidata's recent expansion into the field of real-world evidence and analysis through powerful modeling and simulation techniques speaks volumes about how virtual worlds will drive a new generation of patient engagement. We are in a strong position to transform the life sciences industry, which fully demonstrates dassault's mission to promote the harmonious development of products, nature and life." Medidata's clinical expertise and cloud solutions support the development and commercialization of smarter treatment solutions to 1,300 customers worldwide, including pharmaceutical and biotechnology companies, contract research institutions (CRO), and medical centers and sites. Its solutions can improve decision-making, accelerate process implementation, strengthen supervision, minimize operational risks, reduce costs and adjust clinical trial programs, greatly improving the efficiency and quality of clinical development projects. Medidata technology was used in 13 of the world's top 15 best-selling drugs in 2018. Medidata customers include 18 of the top 25 pharmaceutical companies and 9 of the top 10 CRO companies. Founded in 1999, Medidata is headquartered in New York and employs 2,800 people in 16 offices in seven countries, including the us, Japan, South Korea and the UK. Tarek Sherif, Medidata's chairman, co-founder and chief executive officer, said: "our mission to deliver precision care to patients who need it most, at the right time, is the driving force behind our 20-year innovation and our commitment to the life sciences industry. We share the same vision, values and passion with dassault systems, and together we will promote the life sciences industry through an end-to-end business platform." Glen DE Vries, co-founder and President of Medidata, said, "promoting new therapeutic innovations and creating a new generation of standards of care is a commitment we made right from the start. We will ultimately bring great opportunities for our customers and patients to advance the life sciences in the era of precision medicine." Dassault systems has been committed to the harmonious development of products, nature and life since 2012. Since then, dassault systems has been steadily promoting relevant knowledge and professional technology, promoting the transformation of product field and developing into collaborative and interdisciplinary biotechnology innovation field. Dassault systems has cooperated with 20 top biopharmaceutical companies, hundreds of biotechnology companies, medical device manufacturers, research institutions and government regulatory authorities to develop and launch innovative medical products and technologies, making full use of virtual world technologies to realize the transformation of patient experience.

The acquisition is expected to close in the last quarter of 2019, subject to regulatory approval and majority shareholder approval of Medidata, as well as other customary closing conditions.

About PuXin

As the leading industrial information solution provider, dassault is committed to providing dassault system products to customers in the fields of electronic communication, new materials, new energy vehicles and general aviation. We have an excellent technical service team to bring value to customers of different industries and sizes. For more information, please visit: www.pousensys.com